



Software for
Business Intelligence

BizInt Smart Charts

BizInt Smart Charts Drug Development Suite 5.4

Time to update your software!



The journey continues

John Willmore, BizInt Solutions

19 January 2022

www.bizint.com



www.bizint.com

Today's Topics


- Reference Rows changes
- Color Code Cells
- New columns and templates
- Technique: Evaluating search coverage
- Q&A

Common Drug Name / Trial ID

- Automatically generated when charts are combined or updated
- This was a major training issue in the past
- If you are modifying the common ID, do it after combine/update

Reference Rows Workflow Changes

- You can Send To Reference Rows at any time
- Chart does not need to be saved
- Chart can come from a single database
- No wizard



Combined: MCC Combined - March 2021

	Drug Name	Common Drug Name	Database	Developer	Highest Phase (Normalized)	Therapeutic Activity	Route of Admin	Update Date
1	ADUS-100	ADUS-100	GlobalData Drugs	Chinook Therapeutics Inc	Discontinued	L03AX Other immunostimulants	Intratumor Intravesical	2020-11-26
2	ALRN-6924	ALRN-6924	GlobalData Drugs	Aileron Therapeutics Inc	Phase 2	L01XX Other antineoplastic agents	Intravenous	2021-03-04
3 a	nogapendekin alfa	ALT 803	GlobalData Drugs	Altor Bioscience LLC	Phase 3	J05AR Antivirals for treatment of HIV infections, combinations L03AC Interleukins	Intraperitoneal Intravenous Intravesical Parenteral Subcutaneous	2021-03-25
3 b	Inbakicept - ImmunityBio	ALT 803	Adis R&D Insight	Altor BioScience Corporation (Originator) NantKwest (Originator)	Phase 2/3	J1X (Other Antibacterials) J5 (Antivirals for Systemic Use) L1X (All Other Antineoplastics) L1X9 (All other antineoplastics) L3A (Immunostimulating Agents Excluding Interferons)	Intraperitoneal Intravesicular IV Parenteral SC	2021-03-11
e	ALT 803	ALT 803	Citalisa	Altor BioScience	Phase 2	Fusion protein	Injectable	2020-12-24

Reference Rows Appearance Changes

New Selection Glyphs

Singleton rows have simple row numbers


Source rows now have a letter instead of a decimal number

Combined: MCC Combined - March 2021

	Drug Name	Common Drug Name	Database	Developer
1	ADUS-100	ADUS-100	GlobalData Drugs	Chinook Therapeutics Inc
2	ALRN-6924	ALRN-6924	GlobalData Drugs	Aileron Therapeutics
3 a	nogapendekin alfa	ALT 803	GlobalData Drugs	Altor Biosciences
3 b	Inbakicept - ImmunityBio	ALT 803	Adis R&D Insight	Altor BioSciences Corporation (Orion) NantKwest (Orion)
3 c	ALT 803	ALT 803	Citalin	Altor BioSciences


Hide Reference Rows

- The #1 most requested feature in BizInt Smart Charts is now here! **Hide Reference Row**
- Right click on any component row in a Reference Row to hide the entire group.
- All rows are hidden when you return to Smart Charts



View | Reference Rows

- With View | Reference Rows you can hide, show, and rearrange the Reference Rows in your chart
- The green number on some rows is the number of visible source rows in the group.




Reference Rows Behavior Changes

- Hidden source rows are now part of reference rows
- Hidden moves will move with the selected row (when you return to BizInt Smart Charts)
- Hide/unhide of reference row could bring back source rows which were previously hidden
- Learn more about the new Reference Rows features at bizint.com/support/use/RR_New_Workflow.php

Color Coding Cells



- The old “Highlight Cell” feature is now “Color Code Cells”
- Color chooser to directly select a color (or clear)
- “Color Code Cell” toggles the selection to the color or clear (same behavior with the button)
- Color Codes survive Combine Charts operation
color of the “key” chart is retained

- bizint.com/support/use/color_coding_cells.php



Color Coding Cells

- Choice of eight colors for color coding added in Version 5.3



A screenshot of a software window displaying a table with three columns: 'Common Drug Name', 'Database', and 'Mechanism of Action'. The table contains three rows of data, each with a different background color for the 'Common Drug Name' cell. A 'Color Cells' dialog box is overlaid on the table, showing the same eight color swatches as in the previous screenshot.







Common Drug Name	Database	Mechanism of Action
ALT-803	Adis R&D Insight	Interleukin
ALT-803	Citeline Pharmaprojects	Interleukin Immuno-o
ALT-803	GlobalData Drugs	Cytokine R Subunit Ga Receptor S GammaC

Color Coding Cells

BizInt Smart Charts

for Patents

- Use color coding in user-added columns when combining charts

PatBase: Feature A Search			PatBase: Feature A+B Search							Patent Assignee	Feature B		
Patent Number	Patent Date		Patent Number	Patent Date	Title	Image	International Patent Class	Patent Assignee	Feature A	Feature B			
1	CN112496450A	2021-03-16	1	CN112496450A	2021-03-16	A disassembly convenient hand saw blade (Machine translation)		B23D49/12 B23D51/10 B23D51/12	ZHEJIANG LUCHENG TOO MACHINERY CO LTD	Not applied		CLEAN CUTTERS LLC	
2	US10610939B	2020-04-07	2	US10610939B	2020-04-07	DUSTLESS ONE-STROKE CUT-THROUGH SAW		B23D49/00 B23D49/10 B23D51/01 B23D51/04 B27G5/02	CLEAN CUTTERS LLC			U M KOGYO INC	
3	JP6598281B1	2019-10-30	3	JP6598281B1	2019-10-30	HAND SAW		B23D49/10 B23D49/12 B23D49/14 B23D61/12 B27B21/00 B27B21/04 B27B33/10	U M KOGYO INC			U M KOGYO INC	
4	TWM566122Y	2018-09-01	4	TWM566122Y	2018-09-01	HAND SAW		B23D49/12	U M KOGYO INC	Uses similar approach		PAN DEMIAO	See claim 3
5	TWM549122Y	2017-09-21	5	TWM549122Y	2017-09-21	HAND SAW		B23D49/10	U M KOGYO INC			KANG JIANPING	Possibly too specific
6	CN106956036A	2017-07-18	6	CN106956036A	2017-07-18	PORTABLE FIBER ROPE HAND SAW DEVICE		B23D57/00	JIANGSU WENFENG CHEMICAL FIBER GROUP CO LTD			ZHAO CHUNYUN	

Normalized Phase Columns

- Highest Phase (Normalized)
- Available in all pipeline databases
- Uses Arabic numerals (e.g. Phase 2)
- bizint.com/support/use/normalized_phase.php

Database	Highest Status	Highest Phase (Normalized)
GlobalData Drugs	Discontinued	Discontinued
GlobalData Drugs	Phase II	Phase 2
Adis R&D Insight	Phase II/III	Phase 2/3
Citeline Pharmaprojects	Phase III Clinical Trial	Phase 3
GlobalData Drugs	Phase III	Phase 3
GlobalData Drugs	Phase III	Phase 3
Adis R&D Insight	Phase II	Phase 2
Citeline Pharmaprojects	Phase II Clinical Trial	Phase 2
Cortellis from Clarivate Analytics	Phase 2 Clinical	Phase 2



Normalized Phase Columns

- Indication Phase (Normalized)
- Highest phase per indication

Database	Drug Development Phase			Indication Phase (Normalized)	
	Disease	Status	Country	Indication	Phase
Adis R&D Insight	Bladder cancer	Phase II/III	USA	Bladder cancer	Phase 2/3
	Non-small cell lung cancer	Phase II	USA	Non-small cell lung cancer	Phase 2
	Pancreatic cancer	Phase II	USA	Pancreatic cancer	Phase 2
	Merkel cell carcinoma	Phase II	USA	Merkel cell carcinoma	Phase 2
	Acute myeloid leukaemia	Phase II	USA	Acute myeloid leukaemia	Phase 2
	Squamous cell cancer	Phase III	USA	Squamous cell cancer	Phase 1/2
	Liver cancer	Phase III	USA	Liver cancer	Phase 1/2
	Breast cancer	Phase III	USA	Breast cancer	Phase 1/2
	Colorectal cancer	Phase III	USA	Colorectal cancer	Phase 1/2
	Solid tumours	Phase III	USA	Solid tumours	Phase 1/2
	Multiple myeloma	Phase III	USA	Multiple myeloma	Phase 1/2
	Haematological malignancies	Phase III	USA	Haematological malignancies	Phase 1/2
	Non-Hodgkin's lymphoma	Phase III	USA	Non-Hodgkin's lymphoma	Phase 1/2
	Fallopian tube cancer	Phase I	USA	Fallopian tube cancer	Phase 1
	Peritoneal cancer	Phase I	USA	Peritoneal cancer	Phase 1
	Ovarian cancer	Phase I	USA	Ovarian cancer	Phase 1
	HIV infections	Phase I	USA	HIV infections	Phase 1
	Squamous cell cancer	Phase I	USA	Bacterial infections	No Development Reported
	Solid tumours	No development reported (I)	USA		
	Bacterial infections	No development reported (Preclinical)	USA		
Citeline Pharmaprojects	Cancer, bladder	Phase III Clinical Trial		Cancer, bladder	Phase 3
	Cancer, pancreatic	Phase II Clinical Trial		Cancer, pancreatic	Phase 2
	Cancer, lymphoma, B-cell	Phase II Clinical Trial		Cancer, lymphoma, B-cell	Phase 2
	Cancer, lymphoma, B-cell	Phase II Clinical Trial		Cancer, lymphoma, non-Hodgkin's	Phase 2

Editor's Choice chart templates

- New templates as a starting point



Technique: Evaluating your search strategy


- Reference Rows works best when you have each publisher's version of a drug profile or trial report
- This is a little trick using Excel to evaluate your coverage.

- bizint.com/support/use/statistics.php

Technique: Evaluating your search strategy

- Start by using the Statistics tool in BizInt Smart Charts to count Common Drug Name

Common Drug Name	Database	Developer
ADUS-100	GlobalData Drugs	Chinook Therapeutics
ALRN-6924		
ALT 803		
ALT 803		
ALT 803		



Select a Column

Select a column to analyze from the list of visible columns below

- Common Drug Name
- Database
- Developer
- Drug Name
- Highest Phase (Normalized)
- Route of Admin
- Therapeutic Activity
- Update Date

OK Cancel Help

Generic Statistics Options

Specify how values are separated in this column:

- Separate lines
- Semi-colon (;)
- Spaces
- Count entire cell as one value

OK Cancel Help

Technique: Evaluating your search strategy

- Insert a Pivot Table, and set the columns as below

A	B
Common Drug Name	Count
ADUS-100	1
ALRN-6924	1
ALT 803	3
AMG 232	4
anti-MCPyV T-cell therapy (Mer	1
atezolizumab	2
ATN-161	1
avelumab	4
Avelumab companion diagnosti	1
bempegaldesleukin	2
berdazimer sodium	1
bevacizumab	1
BNT-122	1
BT-001	1
cabozantinib s-malate	2
cancer therapy, Alpha Tau Medic	1
Cavrotolimod	4
Cellular Immunotherapy 2 for O	1

PivotTable Fields

Choose fields to add to report:

Search

Common Drug Name
 Count
More Tables...

Drag fields between areas below:

Filters	Columns
	Count

Rows	Values
	Count of Count

	1	2	3	4	Grand Total
Count of Count	51	19	11	10	91

VP-SCE Version 12

- VP-SCE Version 12 is now available
- Some of the new visualizations and features in V.12
- Visit our webinars page



www.bizint.com

Past Webinars (with recordings)

We have presented webinars showcasing the variety of data types supported by the BizInt Smart Charts family. You can find links to recordings of past webinars by data type below. Or you can [browse our full collection of recorded webinars](#).

▶ Patents and IP Sequences

▶ Drug Pipelines

▶ Clinical Trials

▼ Analysis & Visualization

- **What Can You Do with VantagePoint - Smart Charts Edition v12?**

November 2021 | [Recording](#)

- **Build the bullseye with VP-SCE v11**

January 2020 | [Recording](#)

- **Learn the Key Features of VP-SCE v.11 by Creating a Trials Piano Chart**

December 2019 | [Recording](#), [Handout](#)

So time to update your software!

- This is a good time to put in a request with your IT department to get version 5.4 installed
- We're always updating the software 😊
- While you're at it, VP-SCE Version 12 is available now



Software for
Business Intelligence

BizInt Smart Charts

Questions? Requests?

email us:

support@bizint.com



The journey continues